Ignite Creation Date:
2025-12-24 @ 6:39 PM
Ignite Modification Date:
2025-12-25 @ 4:09 PM
Study NCT ID:
NCT02049957
Status:
COMPLETED
Last Update Posted:
2023-02-08
First Post:
2013-12-12
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer
Sponsor:
Calithera Biosciences, Inc
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-02-13
Start Date Type:
ACTUAL
Primary Completion Date:
2018-06-29
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-06-29
Completion Date Type:
ACTUAL
First Submit Date:
2013-12-12
First Submit QC Date:
None
Study First Post Date:
2014-01-30
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2019-06-28
Results First Submit QC Date:
None
Results First Post Date:
2020-01-27
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-02-06
Last Update Post Date:
2023-02-08
Last Update Post Date Type:
ACTUAL